People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...